Literature DB >> 10226744

Spinal muscular atrophy: molecular pathophysiology.

N H Gendron1, A E MacKenzie.   

Abstract

Spinal muscular atrophy is an autosomal recessive disease characterized by motor neurone loss, muscle atrophy and weakness. Deletion or mutation of the SMN1 gene reduces intracellular survival motor neurone protein levels causes spinal muscular atrophy, most likely by interfering with spliceosome assembly. A range of clinical severity and corresponding survival motor neurone levels is seen because of the presence of copies of the transcriptionally inefficient SMN2 gene and possibly other modifying genes. The delineation of SMN1 as the gene that causes spinal muscular atrophy and the identification of genes that modify spinal muscular atrophy raise the prospect of gene therapy or in-vivo gene activation treatment for this frequently fatal disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226744     DOI: 10.1097/00019052-199904000-00002

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  3 in total

1.  Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy.

Authors:  Mimoun Azzouz; Thanh Le; G Scott Ralph; Lucy Walmsley; Umrao R Monani; Debbie C P Lee; Fraser Wilkes; Kyriacos A Mitrophanous; Susan M Kingsman; Arthur H M Burghes; Nicholas D Mazarakis
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

2.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

3.  Drug treatment for spinal muscular atrophy type I.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.